CA3253955A1 - Annexine a5 monomère pour une utilisation dans le traitement de l'oedème maculaire ou d'une occlusion d'une veine rétinienne - Google Patents

Annexine a5 monomère pour une utilisation dans le traitement de l'oedème maculaire ou d'une occlusion d'une veine rétinienne

Info

Publication number
CA3253955A1
CA3253955A1 CA3253955A CA3253955A CA3253955A1 CA 3253955 A1 CA3253955 A1 CA 3253955A1 CA 3253955 A CA3253955 A CA 3253955A CA 3253955 A CA3253955 A CA 3253955A CA 3253955 A1 CA3253955 A1 CA 3253955A1
Authority
CA
Canada
Prior art keywords
protein
annexin
subject
monomeric
molecule consisting
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3253955A
Other languages
English (en)
Inventor
Anna FROSTEGÅRD
Anders Haegerstrand
Original Assignee
Annexin Pharmaceuticals AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB2207263.1A external-priority patent/GB202207263D0/en
Application filed by Annexin Pharmaceuticals AB filed Critical Annexin Pharmaceuticals AB
Publication of CA3253955A1 publication Critical patent/CA3253955A1/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne de nouveaux procédés, utilisations et compositions d'une molécule consistant en une protéine d'annexine A5 monomère, pour la prophylaxie ou le traitement d'un oedème maculaire et/ou d'une ou de plusieurs maladies, troubles ou états associés à, et/ou provoqués par, un oedème maculaire. Dans un mode de réalisation préféré, l'annexine A5 est administrée par voie systémique, par exemple par voie intraveineuse.
CA3253955A 2022-05-18 2023-05-18 Annexine a5 monomère pour une utilisation dans le traitement de l'oedème maculaire ou d'une occlusion d'une veine rétinienne Pending CA3253955A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB2207263.1A GB202207263D0 (en) 2022-05-18 2022-05-18 Therapeutic compositions
GB2207263.1 2022-05-18
PCT/EP2023/063441 WO2023227468A1 (fr) 2022-05-18 2023-05-18 Annexine a5 monomère pour une utilisation dans le traitement de l'oedème maculaire ou d'une occlusion d'une veine rétinienne

Publications (1)

Publication Number Publication Date
CA3253955A1 true CA3253955A1 (fr) 2023-11-30

Family

ID=96808785

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3253955A Pending CA3253955A1 (fr) 2022-05-18 2023-05-18 Annexine a5 monomère pour une utilisation dans le traitement de l'oedème maculaire ou d'une occlusion d'une veine rétinienne

Country Status (3)

Country Link
US (1) US20250339491A1 (fr)
CA (1) CA3253955A1 (fr)
ES (1) ES3034835T3 (fr)

Also Published As

Publication number Publication date
ES3034835T3 (en) 2025-08-25
US20250339491A1 (en) 2025-11-06

Similar Documents

Publication Publication Date Title
US11071780B2 (en) Methods and formulations for treating vascular eye diseases using aflibercept and nesvacumab
US20140011809A1 (en) Drug delivery to the anterior and posterior segments of the eye using eye drops
BR112020010659A2 (pt) uso de um antagonista do vegf para tratar disfunções oftalmológicas angiogênicas
ES3041647T3 (en) Extended, high dose vegf antagonist regimens for treatment of angiogenic eye disorders
US11944663B2 (en) Method for treating angiogenic eye disorders using VEGF antagonists
KR20190093626A (ko) 황반변성의 신규 치료 방법
AU2020230409B2 (en) Method for the treatment of a disease using pigment epithelium-derived factor (PEDF)
US12540171B2 (en) Compositions and methods for treating ocular disease
US20210138032A1 (en) Non-antibody vegf antagonists for the treatment of neovascular glaucoma
US20170224815A1 (en) Method of Preventing and Treating Retinal Microvasculature Inflammation Using C-Met Signaling Pathway Inhibition
KR20220062279A (ko) 안질환의 치료 방법
US20230338483A1 (en) Method for the treatment of a disease using pigment epithelium-derived factor (pedf)
EP4429693B1 (fr) Annexine a5 monomère pour une utilisation dans le traitement de l'oedème maculaire ou d'une occlusion d'une veine rétinienne
US20250339491A1 (en) Monomeric annexin a5 for use in the treatment of macular oedema or retinal vein occlusion
HK40115628A (en) Monomeric annexin a5 for use in the treatment of macular oedema or retinal vein occlusion
HK40115628B (en) Monomeric annexin a5 for use in the treatment of macular oedema or retinal vein occlusion
WO2024236190A1 (fr) Annexine a5 monomère destinée à être utilisée dans le traitement d'un oedème maculaire ou d'une occlusion veineuse rétinienne
Okuma et al. Effect of aflibercept in patients with age-related macular degeneration
US20250381195A1 (en) Methods of Treating Diabetic Macular Edema
KR20260054713A (ko) 노인성 황반 변성 및 당뇨병성 황반 부종의 치료 방법
Mamane Retinitis pigmentosa-associated cystoid macular oedema
EA051980B1 (ru) Расширенные схемы применения высоких доз антагониста vegf для лечения ангиогенных нарушений со стороны глаза

Legal Events

Date Code Title Description
A00 Application filed

Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A00-A101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION RECEIVED - PCT

Effective date: 20241114

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20241212

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST TO REGISTER A DOCUMENT RECEIVED

Effective date: 20241212

A15 Pct application entered into the national or regional phase

Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A15-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: NATIONAL ENTRY REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250212

P18 Priority claim added or amended

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P18-P105 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIORITY CLAIM REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250212

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REGISTER A DOCUMENT REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250212

A00 Application filed

Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A00-A102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: COMPLIANCE REQUIREMENTS DETERMINED MET

Effective date: 20250214

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-P146 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: BSL VERIFIED - NO DEFECTS

Effective date: 20250214

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250218

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD

Year of fee payment: 2

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250514

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250514